IRB Advisor – January 1, 2005
January 1, 2005
View Issues
-
Experts discuss Belmont Report’s impact on research since the 1970s
The Belmont Report has withstood the test of time as a framework for ethical decision making about human subjects research, experts in research ethics say. -
Belmont Report: Are changes needed?
In this Q&A, Bernard Schwetz, DVM, PHD, director of the Office of Human Research Protections (OHRP), discusses the Belmont Reports successes and challenges as the 25th anniversary of its launching has passed. -
IRB differences hamper multicenter trials
IRB processes are so varied from hospital to hospital that they can unnecessarily impede multicenter trials, according to a survey that looked at the responses of 68 hospitals to one study. -
How one study is being conducted soley on-line
The St. Louis-based genomic medicine development company GenoMed is taking a novel approach to testing its hypothesis that inflammation-reducing heart medications can be effective in treating severe complications of influenza. -
Prop 71: A direct role for states in research
Disappointed by a funding gap in the federal support of stem cell research, the citizens of California have made the decision to directly involve the State in the research effort. -
News Brief: FDA moves to strengthen drug safety program
The FDA announced in early November that it was strengthening its safety program for marketed drugs. Lester M. Crawford, DVM, PhD, acting FDA commissioner, says that he has authorized the Center for Drug Evaluation and Research (CDER) to take the following measures.